CTLA4 and breast carcinoma: As in the case of PD-1, the CTLA-4 molecule and its participation in the pathogenesis of neoplastic diseases, including EBV reactivation, is quite well documented in the literature, especially in gastric cancer [53,54], breast cancer [55], and epithelial cancers [56].